- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04931173
Mechanical Bowel Prep Randomized Study
Is Mechanical Bowel Preparation Necessary to Reduce Surgical Site Infection Following Colon Surgery: A Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Background: Colon surgery includes surgery for colon cancer, inflammatory bowel disease and other benign disease such as diverticulitis. In Canada, approximately 21,000 colon surgeries are performed annually. Following colon surgery, the most common complication is surgical site infection (SSI) and rates of up to 25% have been reported. The high volume of colon cancer surgery, coupled with high rates of SSI lead to considerably worse health care outcomes for patients including increased recovery time, length of stay and readmission. Currently, several different bowel preparations to reduce SSI are being used in Canada and there is significant practice variation due to lack of RCTs and conflicting practice guidelines. More recently, several large observational studies and a network meta-analysis have shown that a combination of intravenous antibiotics, mechanical bowel preparation and oral antibiotics (IVA+MBP+OA) is superior to IVA+MBP and IVA alone. Interestingly, these studies also showed that SSI rates for IVA+OA are comparable to IVA+MBP+OA. These data provide a strong rationale to conduct a RCT comparing IVA+OA versus IVA+MBP+OA to determine if MBP is a necessary part of the bowel preparation or if MBP can be safely omitted and the side effects of MBP avoided.
Objectives: Therefore, the objectives are to conduct a multi-centre, parallel, two arm, non-inferiority RCT comparing IVA+MBP+OA versus IVA+OA to reduce SSI following colon surgery.
Methods: The inclusion criteria are any patient (i) undergoing elective colon surgery, (ii) over the age of 18 years and (3) provides informed consent. Eligible patients at 4 centres across Canada will be randomized to one of two groups: IVA+OA+MBP or IVA+OA. The primary outcome for the trial is the overall rate of SSI at 30 days following surgery. Assuming an overall SSI rate of 7% with IVA+MBP+OA and a non-inferiority margin of 4.0%, 1062 patients will be required with a one sided alpha of 0.05 and a power of 80%. This non-inferiority margin was unanimously accepted as clinically meaningful by all of the Site Leads at participating centres. Primary analyses will be performed per-protocol in patients who received treatment as allocated and underwent colon surgery. Overall SSI rates at 30 days following surgery will be compared using a general linear model and non-inferiority will be declared if the upper limit of the one sided 95% confidence interval of the absolute risk difference of overall SSI following surgery does not include 4.0%.
Relevance: This trial will be highly relevant to both patients and physicians as the results will provide definitive, high quality, patient-centred evidence about whether MBP is a necessary part of the optimal bowel preparation to reduce SSI and improve both patient experience and outcomes. These results will have significant potential to change practice in Canada and world-wide.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- undergoing elective colon surgery for benign or malignant disease
- over the age of 18 years
- provides informed consent.
Exclusion Criteria:
- known anaphylaxis to neomycin or metronidazole
- pregnancy or lactation
- chronic renal failure (serum creatinine > 220 umol/L).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Group A: IV and Oral antibiotics (IVA+OA)
Patients will receive cefazolin 2g IV and metronidazole 500 mg IV administered by the anesthesiologist within 60 minutes prior to the skin incision on the day of surgery.
Standardized re-dosing of cefazolin 2g IV will occur every 4 hours and metronidazole 500 mg IV will occur every 8 hours during the surgical procedure.
Following surgery, no further IVA will be given for SSI prophylaxis.
In addition, patients will self-administer 1g neomycin and 1g metronidazole orally at 1500, 1700 and 2300 hours the day before surgery.
Following this, they will not receive any further OAs for SSI prophylaxis.
|
Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
|
Active Comparator: Group B: IV antibiotics, MBP and oral antibiotics (IVA+MBP+OA)
Patients will receive IVA and OA per Group A. In addition, patients will stay on clear fluids and self-administer a 2L polyethylene glycol MBP orally, between 1500 and 2300 hours on the day before surgery.
|
Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Surgical Site Infection Rate
Time Frame: 30 days following date of surgery
|
Rate of overall surgical site infection
|
30 days following date of surgery
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient tolerability of the bowel preparation
Time Frame: 5 minutes (completed in pre-operative holding area on the day of surgery)
|
Validated 9-item questionnaire entitled: "Mayo Clinic Bowel Prep Tolerability Questionnaire" (Scale 1-4; lower score = better outcome)
|
5 minutes (completed in pre-operative holding area on the day of surgery)
|
Length of stay
Time Frame: 2-7 days
|
length of stay in hospital following colorectal procedure
|
2-7 days
|
30-day ER rate
Time Frame: 30 days
|
emergency room visit rate to any hospital within 30 days of surgery
|
30 days
|
30-day readmission rate
Time Frame: 30 days
|
readmission rate to any hospital within 30 days of surgery
|
30 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PJT-165836
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colorectal Surgery
-
Medical University of South CarolinaCompletedColorectal Surgery | Hepatobiliary SurgeryUnited States
-
Gulhane School of MedicineUniversity Hospital, Ghent; Szeged University; University Clinical Centre of... and other collaboratorsCompletedColorectal Disorders | Colorectal SurgeryTurkey
-
York Teaching Hospitals NHS Foundation TrustCompletedColorectal Surgery | Major Abdominal SurgeryUnited Kingdom
-
IHU StrasbourgRecruitingColorectal SurgeryFrance
-
Indiana UniversityCompletedColorectal SurgeryUnited States
-
Wake Forest University Health SciencesWithdrawnColorectal Surgery
-
University of Massachusetts, WorcesterCompleted
-
Helsinki University Central HospitalActive, not recruiting
-
Children's Hospital Medical Center, CincinnatiTerminated
-
York Teaching Hospitals NHS Foundation TrustTerminatedColorectal SurgeryUnited Kingdom